The authors identified only 25 papers that reported drug survival rates at 48 months and noted these papers reported a wide range of survival. In the first-line setting, survival rates ranged from 3–95% for etanercept, 4–100% for adalimumab and 18–79% for infliximab. When the investigators performed an exploratory analysis of TNF inhibitor survival rates in patients receiving etanercept, adalimumab and infliximab monotherapy, they found etanercept had the highest survival rate at each evaluated time point.
You Might Also Like
Also By This Author
Lara C. Pullen, PhD, is a medical writer based in the Chicago area.
- Emery P, Vlahos B, Szczypa P, et al. Long-term drug survival of tumor necrosis factor inhibitors in patients with rheumatoid arthritis. J Rheumatol. 2019 Jun 1. pii: jrheum.181398. [Epub ahead of print]